Vanguard Group Inc. Boosts Holdings in ResMed Inc. (NYSE:RMD)

Vanguard Group Inc. raised its stake in ResMed Inc. (NYSE:RMD - Free Report) by 0.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 18,173,462 shares of the medical equipment provider's stock after buying an additional 160,590 shares during the period. Vanguard Group Inc. owned about 12.37% of ResMed worth $4,156,089,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in RMD. State Street Corp boosted its holdings in ResMed by 1.9% in the third quarter. State Street Corp now owns 6,261,633 shares of the medical equipment provider's stock valued at $1,528,590,000 after acquiring an additional 116,918 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of ResMed by 10.9% in the 3rd quarter. Geode Capital Management LLC now owns 3,858,814 shares of the medical equipment provider's stock valued at $939,114,000 after purchasing an additional 380,383 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of ResMed by 3.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 957,020 shares of the medical equipment provider's stock valued at $218,861,000 after purchasing an additional 32,973 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of ResMed by 0.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 742,411 shares of the medical equipment provider's stock worth $181,237,000 after buying an additional 2,406 shares during the period. Finally, Los Angeles Capital Management LLC raised its stake in ResMed by 60.0% during the fourth quarter. Los Angeles Capital Management LLC now owns 668,908 shares of the medical equipment provider's stock worth $152,973,000 after buying an additional 250,746 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

Remove Ads

Insider Buying and Selling at ResMed

In other ResMed news, CEO Michael J. Farrell sold 8,009 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $236.77, for a total value of $1,896,290.93. Following the completion of the sale, the chief executive officer now owns 455,472 shares in the company, valued at approximately $107,842,105.44. This trade represents a 1.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the completion of the transaction, the director now owns 77,218 shares in the company, valued at $18,695,249.98. The trade was a 2.52 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,940 shares of company stock worth $9,164,385. Corporate insiders own 0.71% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on RMD shares. The Goldman Sachs Group initiated coverage on shares of ResMed in a research report on Thursday, January 16th. They set a "buy" rating on the stock. Morgan Stanley assumed coverage on ResMed in a research note on Wednesday, March 19th. They set an "overweight" rating and a $280.00 target price for the company. JPMorgan Chase & Co. lifted their target price on ResMed from $270.00 to $286.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. StockNews.com upgraded ResMed from a "hold" rating to a "buy" rating in a report on Tuesday. Finally, UBS Group upgraded shares of ResMed from a "hold" rating to a "strong-buy" rating in a research note on Friday, January 31st. One analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, ResMed presently has a consensus rating of "Moderate Buy" and a consensus target price of $249.73.

ResMed Stock Down 0.4 %

Shares of NYSE RMD traded down $0.89 during mid-day trading on Friday, reaching $221.73. 51,668 shares of the company's stock traded hands, compared to its average volume of 949,051. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. The business has a 50-day simple moving average of $234.10 and a 200 day simple moving average of $238.43. The stock has a market cap of $32.56 billion, a P/E ratio of 26.13, a PEG ratio of 1.53 and a beta of 0.74. ResMed Inc. has a 1-year low of $172.19 and a 1-year high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping analysts' consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. On average, analysts expect that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 13th were given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date was Thursday, February 13th. ResMed's payout ratio is currently 25.03%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.